How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,315 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. Full Text available with Trip Pro

A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. To examine the impact of central nervous system (CNS) stimulants on the growth of children with attention-deficit/hyperactivity disorder (ADHD) and assess the efficacy and feasibility of weight recovery interventions on growth.230 children ages 5-12 with ADHD with no history of chronic CNS stimulant usage were randomly (...) assigned to receive daily CNS stimulants (78%, primarily OROS-Methylphenidate [OROS-MPH]) or behavioral treatment (22%) for 30 months. After 6 months, children evidencing a decline in body mass index (BMI) of >.5 z-units were randomized to one of three weight recovery treatments (WRTs): monthly monitoring of height/weight (MON) plus continued daily medication, drug holidays (DH) with medication limited to school days, or daily caloric supplementation (CS) with a 150-kcal supplement plus daily

2019 Journal of the American Academy of Child and Adolescent Psychiatry Controlled trial quality: uncertain

102. Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For). Full Text available with Trip Pro

Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For). Long-term effectiveness studies for ADHD medications are complicated to design well, and no single study design will capture the entire picture. Although randomized controlled trials are the highest level of evidence, most authorities agree that, when you have treatments as efficacious as the ADHD medications (methylphenidate and amphetamine derivatives and prodrugs, atomoxetine (...) , guanfacine, and clonidine), it is neither practical nor ethical to conduct long-term placebo-controlled RCTs. As a consequence, almost all of the RCT evidence for ADHD medications relates to short-term studies. Although these provide strong evidence for short-term efficacy,1 they do not speak to long-term effectiveness. The European Medicines Agency (EMA) recognized the need for additional evidence of long-term effects before granting licenses for medications that will usually be required to be taken

2019 Journal of the American Academy of Child and Adolescent Psychiatry

103. Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. (Abstract)

Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. This study evaluated the efficacy and safety of tipepidine as an add-on to methylphenidate in the drug treatment of attention-deficit/hyperactivity disorder (ADHD).This study was an 8-week, randomized, parallel group, double-blind, placebo-controlled trial recruiting 53 ADHD-diagnosed children. Patients were randomly (...) divided to receive methylphenidate + tipepidine or methylphenidate + placebo for 8 weeks. Participants were assessed using the parent version of ADHD Rating Scale-IV and the Clinical Global Impression scale at baseline, at week 4, and at the end of the trial. Moreover, the safety and tolerability of the treatment strategies were compared.On general linear model repeated measures analysis a significant effect was seen for time × treatment interaction on the total and hyperactivity-impulsivity subscales

2019 Psychiatry and clinical neurosciences Controlled trial quality: predicted high

104. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. (Abstract)

Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Attention deficit/hyperactivity disorder (ADHD) can be comorbid with frequent anxiety and mood disorders, as well as emotional symptoms (anxiety, irritability, mood lability). These may also be triggered by drugs and appear as adverse drug reactions (ADRs).We mined (...) data from the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database, focused on methylphenidate, atomoxetine, amphetamine, lisdexamfetamine, and their derivatives. We collected reports of ADRs connected with mood or emotional symptoms in pediatric patients, excluding drug abuse/accidents. Reporting odds ratios (RORs) were calculated and compared between drug classes and children/adolescents.We collected 6176 ADRs of interest of which 59% occurred in children

2019 Journal of Clinical Psychopharmacology

105. The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder. Full Text available with Trip Pro

The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder. N-(4-fluorophenyl)-N'-phenyl-N"-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine [ASP2905] is a potent and selective inhibitor of the potassium voltage-gated channel subfamily H member 3 (KCNH3) that was originally identified in our laboratory. KCNH3 is concentrated in the forebrain, and its overexpression in mice leads to cognitive deficits. In contrast, Kcnh3 knockout mice exhibit (...) prefrontal cortex (0.03, 0.1 mg/kg, po; 0.1, 1 mg/kg, po, respectively). The activities of these neurotransmitters are closely associated with attention. We used a multiple-trial passive avoidance task to investigate the effects of ASP2905 on inattention and impulsivity in juvenile stroke-prone spontaneously hypertensive rats. ASP2905 (0.1 and 0.3 mg/kg, po) significantly prolonged cumulative latency as effectively as methylphenidate (0.1 and 0.3 mg/kg, sc), which is the gold standard for treating ADHD

2018 PLoS ONE

106. Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder | Topics A to Z | CKS | NICE Search CKS… Menu Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder Last revised in May 2018 Attention deficit hyperactivity disorder (ADHD) is a behavioural syndrome characterized by hyperactivity, impulsivity, and inattention. Diagnosis Management Prescribing information Background information Attention deficit hyperactivity disorder: Summary Attention (...) deficit hyperactivity disorder (ADHD) is a behavioural syndrome characterized by hyperactivity, impulsivity, and inattention. ADHD should be suspected if the core symptoms of hyperactivity, inattention, and/or impulsivity have been present since childhood. These core symptoms are age-inappropriate and result in significant psychological, social, and/or educational functional impairment. When assessing a child with possible ADHD it is important to note that: Symptoms typically appear in children 3–7

2015 NICE Clinical Knowledge Summaries

107. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence

of this assessment has been made for the HTA database. Citation CADTH. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No conclusions can be drawn regarding the abuse potential of atomoxetine due to the limited data available. Misuse of methylphenidate and amphetamine-based ADHD drugs was found (...) Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2014 Health Technology Assessment (HTA) Database.

108. [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]

disorder using a common comparator] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-13-005. 2013 Authors' conclusions In this research, an indirect comparison methodology used in the context of Health Technology Assessment (HTA). As an example of HTA using indirect comparison, the efficacy of Atomoxetine and Methylphenidate in Adults Attention Deficit Hyperactivity Disorder(ADHD): A Rapid Review conducted by full term for NECA in 2012 was selected as an exemplar. Indirect (...) the significance of treatment effectiveness in clinical usage. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adrenergic Uptake Inhibitors; Adults; Attention Deficit Disorder with Hyperactivity; Meta-Analysis as Topic; Methylphenidate Language Published Korean Country of organisation South Korea English summary An English language summary is available. Address for correspondence National Evidence-based Healthcare Collaborating Agency (NECA), Changkyung B/D 9F, Wonnam-dong 28-7

2013 Health Technology Assessment (HTA) Database.

109. Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. (Abstract)

Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated

2016 JAMA

110. Review of the evidence for the management of co-morbid Tic disorders in children and adolescents with attention deficit hyperactivity disorder Full Text available with Trip Pro

Review of the evidence for the management of co-morbid Tic disorders in children and adolescents with attention deficit hyperactivity disorder Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children and adolescents, with prevalence ranging between 5% and 12% in the developed countries. Tic disorders (TD) are common co-morbidities in paediatric ADHD patients with or without pharmacotherapy treatment. There has been conflicting evidence (...) . Supratherapeutic doses of dextroamphetamine have been shown to exacerbate TD. Most tics are mild or moderate and respond to psychoeducation and behavioural management. Level A evidence support the use of alpha adrenergic agonists, including Clonidine and Guanfacine, reuptake noradrenenaline inhibitors (Atomoxetine) and stimulants (Methylphenidate and Dexamphetamines) for the treatment of Tics and comorbid ADHD. Priority should be given to the management of co-morbid Tourette's syndrome (TS) or severely

2018 World journal of clinical pediatrics

111. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder Full Text available with Trip Pro

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed (...) by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients

2018 European addiction research

112. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. (Abstract)

Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. The aim of this study was to compare children and adolescents with attention-deficit/hyperactivity disorder (ADHD) to healthy children and adolescents in terms of state and trait empathy and emotion expression recognition skills. The goal was also to determine whether (...) there are changes in emotion recognition and empathy measures in children with ADHD after methylphenidate (MPH) treatment.The research sample consisted of outpatient drug-naive children and adolescents between the age of 8 and 14 years (n = 65) with ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria, and healthy children and adolescents of the same age (n = 61). Scores of the oppositional problems (OPs) and conduct problems (CPs) were obtained to evaluate their impact

2017 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

113. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol]

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

114. Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review

Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

115. Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder 1 Quality Department Guidelines for Clinical Care Ambulatory ADHD Guideline Team Team Leaders John M O'Brien, MD Family Medicine Jennifer G. Christner, MD Child Behavioral Health Team Members Bernard Biermann, MD, PhD Child/Adolescent Psychiatry Barbara T Felt, MD Child Behavioral Health R Van Harrison, PhD Medical Education Paramjeet K Kochhar, MD General Pediatrics Consultant Darcie-Ann Streetman, PharmD College of Pharmacy Initial Release August, 2005 (...) of child’s self-identified impression of function, both strengths and weaknesses • Clinician’s observations of child’s behavior • Physical and neurologic examination Note: From ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, American Academy of Pediatrics, Nov. 2011 Table 4. Treatment Options for ADHD For pre-school aged children, first line is behavior therapy. If not significantly improved, prescribe

2013 University of Michigan Health System

116. Family-based association study of DRD4 gene in methylphenidate-responded Attention Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

Family-based association study of DRD4 gene in methylphenidate-responded Attention Deficit/Hyperactivity Disorder. The 48-basepair (48-bp) variable number tandem repeat (VNTR) polymorphism in exon 3 of the dopamine receptor D4 gene (DRD4) is implicated in the etiology of attention-deficit/ hyperactivity disorder (ADHD). In particular, ADHD in European-ancestry population is associated with an increased prevalence of the 7-repeat (7R) allele of the exon 3 VNTR. However, it is intriguing to note (...) of an association between ADHD and 2R allele in Chinese population does not exactly contradict the original 7R allele finding in European-ancestry population. However, given the potential pitfall of population stratification in the previous case-control design, this current study tested the 2R allele and ADHD association using a methodologically more rigorous family-based approach on 33 Chinese ADHD probands who had favorable clinical responses to stimulant medication (methylphenidate). Haplotype Relative Risk

2017 PLoS ONE

117. Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder. (Abstract)

Effect of vitamin D treatment in children with attention-deficit hyperactivity disorder. In this research the symptom improvement of attention-deficit hyperactivity disorder (ADHD) of children was assessed by oral vitamin D administration in Tabriz, Iran.In this double-blind, randomized clinical trials, 96 children (2-18 years) were enrolled to placebo and vitamin D groups. Children took vitamin D pearl (50,000 IU/week) or placebo for 6 weeks. Children, who had the change in methylphenidate (...) dosage and received any anticonvulsants and corticosteroids were excluded from the research. ADHD symptoms were diagnosed by Conners parent rating scale (CPRS) test at baseline and after intervention. ADHD Conners divided into inattention (IA), hyperactivity/impulsivity (H/I) and combination type (C) subscales. Vitamin D serum level was assessed at baseline and after 8 weeks in both groups.The differences between CPRS and its subscales were not significant at baseline (P > 0.05). The Conners IA score

2018 World journal of pediatrics : WJP Controlled trial quality: uncertain

118. Effects of Mindful Parenting Training on Clinical Symptoms in Children with Attention Deficit Hyperactivity Disorder and Parenting Stress: Randomized Controlled Trial. (Abstract)

Effects of Mindful Parenting Training on Clinical Symptoms in Children with Attention Deficit Hyperactivity Disorder and Parenting Stress: Randomized Controlled Trial. Children with attention deficit hyperactivity disorder (ADHD) are at risk of impairment in multiple domains. This study aimed to investigate the effectiveness of mindful parenting training in reducing clinical symptoms in children with ADHD and parenting stress of their parents.This randomized clinical trial was conducted on 2 (...) groups (experimental and control) in 3 phases (pretest, posttest, and 8 weeks' follow-up). Sixty children with ADHD, who had been referred by the child psychiatrist in the Iranian city of Kashan in the second half of the year 2016, were selected along with their mothers. The mothers were assigned to one of the 2 groups via permuted blocked randomization. The mothers completed the parenting stress index-short form (PSI-SF 36) and the Swanson, Nolan, and Pelham Parent and Teacher rating scale (SNAP-IV

2018 Iranian journal of medical sciences Controlled trial quality: uncertain

119. Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder. (Abstract)

Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder. Neurofeedback (NF) is an operant conditioning procedure that trains participants to self-regulate brain activity. NF is a promising treatment for attention-deficit/hyperactivity disorder (ADHD), but there have been only a few randomized controlled trials comparing the effectiveness of NF with medication with various NF protocols. The aim of this study was therefore to evaluate the effectiveness (...) of unipolar electrode NF using theta/beta protocol compared with methylphenidate (MPH) for ADHD.Children with newly diagnosed ADHD were randomly organized into NF and MPH groups. The NF group received 30 sessions of NF. Children in the MPH group were prescribed MPH for 12 weeks. Vanderbilt ADHD rating scales were completed by parents and teachers to evaluate ADHD symptoms before and after treatment. Student's t-test and Cohen's d were used to compare symptoms between groups and evaluate the effect size

2018 Pediatrics international : official journal of the Japan Pediatric Society Controlled trial quality: uncertain

120. An Investigation of Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

An Investigation of Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder. Stimulant medications are the most commonly prescribed treatment for Attention-Deficit/Hyperactivity Disorder (AD/HD). These medications result in a normalization of the EEG. However, past research has found that complete normalization of the EEG is not always achieved. One reason for this may be that studies have used different medications interchangeably, or groups of subjects (...) on different stimulants. This study investigated whether methylphenidate and dexamphetamine produce different levels of normalization of the EEG in children with AD/HD. Three groups of 20 boys participated in this study. There were 2 groups with a diagnosis of AD/HD; one group, good responders to methylphenidate, and the second, good responders to dexamphetamine. The third group was a normal control group. Baseline EEGs were recorded using an eyes-closed resting condition, and analyzed for total power

2018 Clinical EEG and Neuroscience Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>